Targepeutics Inc., of Hershey, Pa., received U.S. Patent No. 6,884,603 for its genetically modified, mutated interleukin-13 technology platform for the treatment of malignant glioma.

Targeted Genetics Corp., of Seattle, said U.S. Patent No. 6,897,045, titled "Adeno-Associated Virus Vectors," relating to the company' technology platform, was issued to the University of Iowa Research Foundation. The patent is exclusively licensed to Targeted Genetics.